-
FDA Accelerated Approval for Padcev – (Enfortumab-vedotin)
News from late December 2019,
FDA Approves Padcev (enfortumab vedotin-ejfv) for Locally Advanced or Metastatic Urothelial Cancer, the Most Common Type of Bladder Cancer.
Another option to look into for those of us who are not good surgical candidates. I could not join the study because of other medical problems, but it was one of two that looked promising. Info at
Best to all, Jack
6/2015 HG Papillary & CIS
3 Years and 30 BCG/BCG+Inf
Tis CIS comes back.
BC clear as of 5/17 !
RCC found in my one & only kidney 10/17
Begin Chemo; Cisplatin and Gemzar
8/18 begin Chemo# 3
Begin year 4 with cis
2/19 Chemo #4
9/19 NED again :)
1/2020 CIS is back
Tried Keytruda, stopped by side effects
Workin on a new plan for 2021Sorry, there were no replies found.
Sign In to reply.